Tort Experts’ Post

Read my Medscape article on the responsible use of compounded GLP-1s in Obesity care. Instead of a complete ban, we should guide their usage safely and in line with the FD&C Act. This approach can be especially beneficial for patients with cardiovascular disease during branded medication shortages. Check it out! #GLP1s #ObesityCare #FDCA #PatientSafety

Exciting News in Healthcare! According to Biopharma Dive, Medicare is set to reimburse Novo Nordisk's Wegovy for treating obesity and heart disease. Wegovy, which is already approved by the FDA for chronic weight management, has shown remarkable efficacy in reducing body weight and addressing related comorbidities, including cardiovascular risks. Now, with Medicare's decision to reimburse for this treatment, millions of individuals struggling with obesity and its associated health complications will have greater access to potentially life-changing care. Check out the article below: #HealthcareInnovation #Wegovy #ObesityTreatment #HeartDisease #MedicareCoverage #NovoNordisk #HealthcareAccessibility

With 1 in 8 people in the world living with obesity, the convenience of online shopping and food delivery has only added to the challenge, especially with previous COVID lockdowns. It is promising to see emerging medications like Ozempic (FDA approved since 2017 for diabetes management) and Wegovy, were once used to manage diabetes, can now assist with weight loss. It is also very interesting to see them being covered by medical insurance to prevent heart attacks and stroke in high risk patients. https://lnkd.in/dCivBAvZ

"You cannot learn what you think you already know." – Epictetus Much of what some prescribers have stated in news stories and even here about compounded drugs is simply inaccurate and misinformed. As Dr. Einav indicates in his piece, FDA-approved drugs should ALWAYS be the first line of therapy. But it's simply not rational, fair, or compassionate to say to a patient when a life-changing medication is in shortage that they'll just need to do without – particularly when compounding pharmacies are using the EXACT SAME API made by the EXACT SAME CONTRACT MANUFACTURERS that supply the drug manufacturers and ADHERING TO THE EXACT SAME FORMULA used by the drug manufacturers (Fun fact: It's printed in the insert for the branded drug). True, compounded drugs are not FDA-approved. That's why they are not a first-line therapy. But FDA approval is no guarantee of safety, and absence of FDA approval does not mean unsafe. Is the risk higher? Perhaps. But it's a leap to jump from "higher-risk" to "unsafe." And all that bluster about not knowing what's in a compounded medication? Total nonsense. Compounded drugs come with a certificate of analysis attesting to purity, plus compounding labs submit their preparations for third party testing.

Taking antibiotics "just in case" may sound harmless, but the data is clear that antibiotics can lead to kidney damage, especially in people with certain medical conditions. And with many infections antibiotics are not even needed at all! #prescriberesponsibly #antibioticresistance #antimicrobialresistance #antimicrobialstewardship #publicheatlh https://lnkd.in/etKvAbky

Nonadherence to oral #antidiabetic medications can worsen disease outcomes and lead to poor #glycemic control, excess #mortality, and increased #morbidity. However, new data presented at #APhA2024 has found that comprehensive #medication reviews can improve adherence in patients with type 2 #diabetes. https://lnkd.in/eqzRsUEb

If the federal government’s proposed list of diabetes medications for national pharmacare is implemented, hospitalizations, specialist interventions, disease complications and premature deaths will increase. Canada’s governments should focus on providing innovative medicines that can decrease the need for other services, reduce complications and extend lives, not on rationing or denying them. #medicines #pharmacare #canada https://lnkd.in/g5QywJkz

The FDA's recent approval of Wegovy for cardiovascular risk reduction opens up new possibilities for managing obesity and cardiovascular disease. 🫀 But it's not just about medication — it's about a holistic approach to health. 💊 Check out our latest blog by Dr. Edo Paz, SVP of Medical Affairs at Hello Heart to learn more about how we can navigate this new frontier together. 💫 https://lnkd.in/eE8RFsHf #semaglutide #cardiovascularhealth #hearthealth #employerbenefits

Opinion | Medicare Can Cover Anti-Obesity Drugs for Heart Disease -- But at What Cost? - Medpage Today: Opinion | Medicare Can Cover Anti-Obesity Drugs for Heart Disease -- But at What Cost?  Medpage Today

🚨 Healthcare Update - Medicare is set to cover a new weight loss drug aimed at reducing the risk of cardiovascular disease. This significant move could benefit many, offering better health outcomes for those at risk. Discover how this change impacts patients and healthcare providers in our latest article. 🔗 Stay informed: https://lnkd.in/eHUmv-PV 📞 For more information, contact: - Isabelle Bibet-Kalinyak, Vice Chair, Healthcare | 973.403.3131 | ibibetkalinyak@bracheichler.com - Michael C. Foster | 973.403.3102 | mfoster@bracheichler.com #Medicare #HealthcareUpdates #CardiovascularHealth #WeightLoss #BrachEichler #PatientCare *This is intended to provide general information, not legal advice. Please contact the authors if you need specific legal advice.